24/7 Market News Snapshot 01 October, 2025 – Entero Therapeutics, Inc. Common Stock (NASDAQ:ENTO)

October 1, 2025

DENVER, Colo., 01 October, 2025 (www.247marketnews.com) – (NASDAQ:ENTO) are discussed in this article.
Entero Therapeutics, Inc. (ENTO) has experienced a notable surge in its stock price, opening at $4.65 and currently trading at $5.673, reflecting an approximate increase of 13.46%. This positive movement follows a previous session close of $5.00, indicating a continuing bullish trend. With a trading volume of 2.00 million shares, investor interest has been significantly heightened, suggesting potential for further price escalation. Observers are advised to closely monitor the stock for potential breakout points and volume trends that may influence future price actions.

In tandem with this market performance, ENTO has announced the strategic acquisition of GRID AI Corp, a prominent provider of AI-driven software and device platforms. This acquisition positions ENTO at the forefront of the rapidly evolving interface of artificial intelligence and energy management. GRID AI has raised over $50 million to advance its innovative solutions, including Dynamic Load Shaping™ (DLS) and the Aggregation Management Platform (AMP), which utilize AI, machine learning, and edge analytics to optimize distributed energy resources (DERs).

In light of projections by Goldman Sachs Research indicating that power demand could increase by as much as 165% by 2030 due to the AI boom, this acquisition offers ENTO a pivotal opportunity to meet rising needs within the energy sector. The integration of GRID AI’s capabilities allows ENTO to provide enhanced solutions for utilities and large-scale energy users, ensuring that the increased technological demands are met efficiently while maintaining grid reliability.

Interim Chief Executive Officer Jason Sawyer emphasized the transformative nature of the acquisition, stating that it not only positions ENTO for growth but also addresses urgent power demands. Post-acquisition, GRID AI will function as a wholly owned subsidiary, reinforcing ENTO’s commitment to both innovative energy solutions and its core focus on developing therapies for gastrointestinal diseases. This strategic move marks a significant chapter in ENTO’s evolution as it seeks to drive value at the intersection of AI and energy.

Related news for (ENTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.